

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

【Cover】

【Document Submitted】	Extraordinary Report
【Submitted to】	Director, Kanto Local Finance Bureau
【Date of Submission】	June 21, 2024
【Company Name】	Ono Yakuhin Kogyo Kabushiki-Kaisha
【Company Name (in English)】	ONO PHARMACEUTICAL CO., LTD.
【Position and Name of Representative】	Toichi Takino, Representative Director, President and Chief Operating Officer
【Location of Head Office】	1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan (The above is the location of the registered head office. The actual head office operations are located at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan.)
【Phone No.】	Not applicable
【Contact for Communications】	Not applicable
【Nearest Contact】	8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan
【Phone No.】	+81-(0)6-6263-5670
【Contact for Communications】	Masaki Itoh, Division Director of Business Management Division
【Place Where Available for Public Inspection】	Tokyo Stock Exchange, Inc. (2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

1 【Reason for Filing】

As the following proposals were resolved at the 76th Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (the "Company") held on June 20, 2024, the Company hereby files this Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and the provisions of Article 19, Paragraph 2, Item 9-2 of the Cabinet Office Ordinance on the Disclosure of Corporate Affairs, etc.

2 【Description of Report】

(1) Date of the Ordinary General Shareholders' Meeting

June 20, 2024

(2) Details of Proposals Resolved

Proposal 1 Appropriation of Surplus

Year-End Dividend

① Type of dividend property

Cash

② Allocation of dividend property to shareholders and total amount of such allocation

¥40 per share of common stock Total dividend amount: ¥18,788,508,720

③ Effective date of the distribution of the dividend

June 21, 2024

Proposal 2 Election of Six (6) Members of the Board of Directors

Six (6) Members of the Board of Directors, namely, Gyo Sagara, Toichi Takino, Toshihiro Tsujinaka, Masao Nomura, Akiko Okuno and Shusaku Nagae were elected.

Proposal 3 Election of Two (2) Audit & Supervisory Board Members

Two (2) Audit & Supervisory Board Members, namely, Kiyooki Idemitsu and Yasuo Hishiyama were elected.

(3) The number of voting rights either approving, disapproving or abstaining on proposals resolved; requirements for the approval of the resolutions and their results

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)
Proposal 1 Appropriation of Surplus	3,925,230	5,294	0	(Note 1)	Approved 99.803
Proposal 2 Election of Six (6) Members of the Board of Directors					
Gyo Sagara	3,714,435	175,457	40,577	(Note 2)	Approved 94.444
Toichi Takino	3,787,116	138,488	4,871		Approved 96.292
Toshihiro Tsujinaka	3,863,400	67,079	0		Approved 98.232
Masao Nomura	3,893,300	33,676	3,504		Approved 98.992
Akiko Okuno	3,909,144	21,337	0		Approved 99.395
Shusaku Nagae	3,895,598	31,378	3,504		Approved 99.050
Proposal 3 Election of Two (2) Audit & Supervisory Board Members				(Note 2)	
Kiyoaki Idemitsu	3,447,220	482,909	165	(Note 2)	Approved 87.654
Yasuo Hishiyama	3,901,976	28,166	165		Approved 99.217

Notes) 1. Proposal 1 requires approval by a majority of voting rights of the shareholders in attendance eligible for exercising voting rights.
2. Proposal 2 and Proposal 3 require the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by the majority of said voting rights.

(4) The reason why a portion of the voting rights held by the shareholders in attendance at the Ordinary General Shareholders' Meeting was not counted

Resolutions of all the proposals have been legitimately reached in accordance with the Companies Act, as the requirements for approval have been met based on the number of confirmed votes of approval or disapproval by counting the voting rights exercised up to the day before this General Shareholders' Meeting and those of shareholders in attendance. Therefore, voting rights of the shareholders in attendance which are not confirmed as to whether they are approving, disapproving, or abstaining are not included in the count.